Similar articles

• Risk-benefit assessment of fluticasone propionate in the treatment of asthma and allergic rhinitis.

  Storms WW. Storms WW. J Asthma. 1998;35(4):313-36. doi: 10.3109/02770909809075665. J Asthma. 1998. PMID: 9669826 Review.
• Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.

  Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, Mahajan P, House KW. Peden DB, et al. J Allergy Clin Immunol. 1998 Jul;102(1):32-8. doi: 10.1016/s0091-6749(98)70052-1. J Allergy Clin Immunol. 1998. PMID: 9679845 Clinical Trial.
• Fluticasone furoate: intranasal use in allergic rhinitis.

  McCormack PL, Scott LJ. McCormack PL, et al. Drugs. 2007;67(13):1905-15. doi: 10.2165/00003495-200767130-00010. Drugs. 2007. PMID: 17722960 Review.
• [Fluticasone propionate--a new name common in asthma and rhinitis].

  Ulmeanu R, Mihălţan F. Ulmeanu R, et al. Pneumoftiziologia. 1997 Jan-Mar;46(1):63-4. Pneumoftiziologia. 1997. PMID: 9289240 Review. Romanian. No abstract available.
• Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control.

  Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Nathan RA, et al. Chest. 2005 Oct;128(4):1910-20. doi: 10.1378/chest.128.4.1910. Chest. 2005. PMID: 16236835 Clinical Trial.